References

References

1. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9-S15.
2. Ali R, Wendt MK. The paradoxical functions of EGFR during breast cancer progression. Signal Transduct Target Ther. 2017;2:16042.
3. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12(1):3-20.
4. Rogers JE, Ohinata A, Silva NN, Mehdizadeh A, Eng C. Epidermal growth factor receptor inhibition in metastatic anal cancer. Anticancer Drugs. 2016;27(8):804-808.
5. Paliga AA, Onerheim R, Gologan A, et al. EGFR expression in invasive anal carcinoma. J Clin Oncol. 2011;29:4_suppl, 412-412.
6. Ravery V, Grignon D, Angulo J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res. 1997;25(1):9-17.
7. Maennling AE, Tur MK, Niebert M, et al. Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials. Cancers. 2019;11(12):1826.
8. Viswanath L, Naveen T, Siddanna P, et al. Epidermal growth factor receptor (EGFR) overexpression in patients with advanced cervical cancer. J Clin Oncol. 2017; 32(15_suppl).
9. Pabla B, Bissonnette M, Konda VJ. Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World J Clin Oncol. 2015;6(5):133-141.
10. Konecny GE, Venkatesan N, Yang G, et al. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer. 2008;98(6):1076-1084.
11. Reyes HD, Thiel KW, Carlson MJ, et al. Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers. Mol Diagn Ther. 2014;18(2):137-151.
12. Li JC, Zhao YH, Wang XY, et al. Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma. Tumour Biol. 2014;35(1):651-657.
13. Wang KL, Wu TT, Choi IS, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome [published correction appears in Cancer. 2009 May 1;115(9):2024. Reseetkova, Erika [corrected to Resetkova, Erika]]. Cancer. 2007;109(4):658-667.
14. Arienti C, Pignatta S, Tesei A. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Front Oncol. 2019;9:1308. Published 2019 Nov 26. doi:10.3389/fonc.2019.01308
15. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 2010;12(9):675-684.
16. Agarwal V, Subash A, Nayar RC, Rao V. Is EGFR really a therapeutic target in head and neck cancers?. J Surg Oncol. 2019;119(6):685-686.
17. Byeon HK, Ku M, Yang J. Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Exp Mol Med. 2019;51:1-14. 
18. da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49-69.
19. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48-51.
20. Mustea A, Koensgen D, Zellinger R, et al. Epidermal growth factor receptor (EGFR) mutation rate in advanced ovarian cancer (AOC): Results of a prospective study in Caucasian patients (pts). J Clin Oncol. 2006;(24):18_suppl.
21. Oliveira-Cunha M, Newman WG, Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer. Cancers (Basel). 2011;3(2):1513-1526.
22. Chiramel J, Backen AC, Pihlak R, et al. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2017;18(5):909.